 |
|
|
| |
Pooled Resistance Analysis in HCV Genotype 1-6 Infected Patients
Treated With Glecaprevir/Pibrentasvir in Phase 2 and 3 Clinical Trials
|
| |
| |
Reported by Jules Levin
52nd Annual Meeting of the European Association for the Study of the Liver, 19-23 April 2017, Amsterdam, the Netherlands
Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, Teresa Ng, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Wangang Xie, Lois Larsen,
Federico Mensa, Tami Pilot-Matias, and Christine Collins
Research and Development, AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
